Xitrin

Quick links to important sections

Xitrin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xitrin

Property Description
Active Ingredients Potassium Citrate, Sodium Citrate
Form Oral Solution (Liquid)
Pharmacological Class Alkalinizing Agent
Origin Synthetic Chemical Salts
General Purpose Management of Acid-Base Balance

Xitrin: Identity and Pharmacological Class

Xitrin is a highly concentrated, prescription-only medication classified as an Alkalinizing Agent used for the management of the body's acid-base balance. It is formulated as a Combination Product that delivers two crucial active ingredients: Potassium Citrate and Sodium Citrate (commonly referred to as Tricitrates). The pharmacological class is categorized as Urinary and Systemic Alkalinizing Agents. This composition is clinically recognized for its ability to modify systemic and urinary pH, supporting its role in maintenance therapy.

The product is composed of synthesized chemical salts derived from citric acid, making its origin pharmaceutical rather than purely natural. This dual-salt composition ensures the introduction of both potassium and sodium electrolytes along with the active citrate component, establishing it as a comprehensive approach among citrate preparations for controlled systemic pH management.


Composition and Form (Oral Solution)

Xitrin is provided as an Oral Solution (a liquid or syrup), which serves as a highly effective vehicle for the active ingredients to be absorbed quickly into the body. The preparation is an aqueous (water-based) liquid that contains the specified doses of Potassium Citrate and Sodium Citrate. Brands like Xitrin often offer a specific, easy-to-mix flavor and precise concentration, which aids in long-term maintenance therapy compliance for patients requiring daily adjustments.

This liquid form is intentionally concentrated to deliver a substantial amount of the citrates in a relatively small volume. Unlike solid dosage forms, the oral solution allows for flexible and incremental dose adjustment, enabling providers to precisely fine-tune the amount administered. This adjustability is essential for achieving and maintaining specific acid-base or urinary pH targets necessary for the patient's long-term management.


General Purpose: Alkalinization and Acid Management

The general purpose of Xitrin is to support the body’s acid-base equilibrium by facilitating Systemic Alkalinization and making the urine less acidic. When absorbed orally, the citrates are metabolized by the body, primarily converting into bicarbonate, a powerful natural buffer. This mechanism is primarily utilized to help prevent the crystallization of salts in the urine.

This generated bicarbonate helps neutralize excess acid in the bloodstream and tissues, thereby raising the overall pH. The benefit is focused on managing states of elevated acidity in the body and, specifically, creating an alkaline environment in the urinary tract. This core function of managing acidity is fundamental to the drug’s role in preventing the formation of certain acid-dependent mineral deposits.

Regulatory References

  1. NIH DailyMed Drug Classes
  2. DailyMed: Tricitrates Monograph (Potassium/Sodium Citrate)
  3. MedlinePlus: Sodium Picosulfate, Magnesium Oxide, and Anhydrous Citric Acid

What side effects are possible with Xitrin?

Possible Side Effects and Safety Information

The official safety profile for Xitrin (Potassium Citrate, Sodium Citrate) is structured by regulatory authorities around potential adverse effects primarily involving the gastrointestinal system and body fluid chemistry.


Common and Expected Adverse Reactions

The most frequently noted adverse reactions are classified as common in regulatory documents and are related to the digestive tract. These include general gastrointestinal discomfort, nausea, vomiting, diarrhea, and abdominal pain or cramping. These effects are often more frequently observed at the start of treatment or during dose escalation, a pattern documented in official labeling.


Serious Adverse Reactions and Safety Constraints

The primary serious risk documented is Severe Hyperkalemia, a potentially life-threatening elevation of serum potassium, particularly in the presence of compromised kidney function. Regulatory labels also document the potential for serious Gastrointestinal Lesions or ulceration associated with oral potassium products.

Safety usage is strictly limited, or contraindicated, in several conditions. These include pre-existing severe renal impairment, active hyperkalemia, and conditions that significantly delay gastrointestinal transit time, as these factors increase the risk of critical complications.


Population-Specific Safety Considerations

Regulatory documents specify that the risk of hyperkalemia is heightened in older adults due to typical age-related decline in renal function. Additionally, patients using Digitalis glycosides (heart medications) face an increased risk of serious cardiac arrhythmias if hyperkalemia develops, requiring particular safety consideration.

Overdose and Emergency Response

Xitrin overdose is officially characterized by severe metabolic and cardiovascular risks due to its dual components, Potassium Citrate and Sodium Citrate. The most serious officially documented outcomes are Hyperkalemia (excessive potassium concentration) and Metabolic Alkalosis (systemic base excess). Due to the potential for lethal potassium levels to be reached rapidly, the regulatory documentation classifies this as a severe, potentially life-threatening event.

Overdose presentations involve a specific symptom profile, including gastrointestinal distress such as nausea, vomiting, and diarrhea. Neuro-muscular manifestations include confusion, weakness, listlessness, and tingling of extremities. The cardiovascular system is primarily affected, with the risk of irregular heartbeat and Electrocardiographic abnormalities potentially leading to cardiac arrest.

Regulatory labeling mandates specific emergency action: Get emergency help immediately or contact a poison control center or emergency room at once upon suspected overexposure. The required management procedure focuses on the immediate Treatment of Hyperkalemia. The risk of severity is documented to be higher in patients with impaired excretory mechanisms or pre-existing renal disease. There is no specific antidote documented for Xitrin overdose; treatment remains strictly supportive and procedural, focusing on correcting the underlying imbalances.

Therapeutic Uses of Xitrin

What Xitrin Treats: Main Uses and Benefits

Xitrin is commonly used in therapeutic domains related to systemic imbalance and managing associated conditions. This medication category is generally applied for long-term management of nephrolithiasis (kidney stone disease) and chronic metabolic acidosis, including situations involving Renal Tubular Acidosis (RTA). This therapy is applied to help make the urine less acidic, which is considered relevant in preventing the formation of specific types of kidney stones.

The key therapeutic function is applied in addressing underlying chemical risks, such as low urinary citrate (hypocitraturia) and persistent high acidity. Supporting the correction of these factors may assist with reducing the risk of future stone episodes and supports the management of systemic discomfort associated with chronic acidosis. By contributing to continuous chemical stability, Xitrin supports the maintenance of functional stability and may assist with coping more steadily with symptom fluctuations, which is relevant when symptoms become more disruptive during flare-ups.


Quick Fact: Relief for Recurrent Stone Risk Xitrin helps manage the risk of future urological discomfort and pain by supporting the body's chemical balance, which is commonly used to help with conditions involving episodic manifestations.

Eligibility and Restrictions for Use

Xitrin is strictly regulated for use based on a patient's pre-existing health status, primarily due to its active components being potassium and sodium salts. The medicine is contraindicated and must not be used in individuals with severe renal impairment accompanied by oliguria or azotemia, or in any patient with hyperkalemia (high potassium levels) from any cause. Absolute prohibitions also apply to patients with untreated Addison's disease, severe myocardial damage, anuria (absence of urine production), acute dehydration, and related conditions.

Use is restricted and requires caution and medical supervision in populations with less severe impaired renal function, cardiac failure, hypertension, or those on a sodium-restricted diet. The official regulatory profile states that the safety and efficacy of Xitrin have not been established in the general pediatric population. For geriatric patients, no specific information is available regarding the relationship of age to the drug's effects. During pregnancy and lactation, use is generally restricted to situations where it is deemed clearly needed.

What should I know about interactions with other medicines?

The official regulatory documentation for Xitrin (Potassium Citrate/Sodium Citrate Oral Solution) describes several interactions, primarily based on the product’s contribution of potassium and its systemic alkalinizing action. The highest level of restriction applies to co-administration with Potassium-sparing Diuretics (such as Amiloride, Spironolactone, and Triamterene), which is formally documented as needing to be avoided due to the risk of severe hyperkalemia.

Other medicinal products require monitoring because of this additive potassium effect, including RAAS Inhibitors (ACE Inhibitors, ARBs, Aliskiren) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which may also lead to elevated serum potassium concentrations. Caution is further advised with Cardiac Glycosides (like Digoxin) since their efficacy is dependent upon stable potassium levels.

Interactions stemming from the alkalinizing function include the requirement to avoid simultaneous use with Methenamine, as the increased pH of the urine reduces its necessary efficacy. A separate exposure-related restriction is documented for Aluminum-based Antacids, which should be avoided in patients with reduced glomerular filtration rates (GFR) due to the risk of increased aluminum absorption and accumulation. Finally, drugs that slow gastrointestinal transit time, such as Anticholinergics, are documented as increasing the risk of local gastrointestinal irritation when used with Xitrin.

Mechanism of Action

The mechanism of Xitrin (Potassium Citrate, Sodium Citrate) involves a direct biochemical process centered on increasing the body's physiological buffering capacity, resulting in changes to pH dynamics. The process involves two primary mechanistic domains: metabolic activation and systemic modulation.


Metabolic Conversion to Bicarbonate

This mechanism involves the drug's primary biological target: the Citric Acid Cycle (Kreb's cycle) enzymes located predominantly in the liver. Once absorbed, the inert citrate ion is metabolized, which chemically yields three molecules of the powerful physiological buffer, bicarbonate ( HCO3^-). This metabolic conversion transforms the salt into the active agent, bicarbonate ( HCO3^-), which initiates the subsequent pH modulation.


Augmenting Systemic and Renal Buffer Capacity

The newly generated bicarbonate enters the circulation, interacting directly with the Bicarbonate-Carbonic Acid Buffer System to bind to H^+ ions. This systemic buffer augmentation raises the overall pH of the plasma and extracellular fluid. The resultant physiological effect is the alkalinization of the urine, achieved as the higher circulating bicarbonate load modifies the pH gradient within the kidneys, ensuring the excreted urine is less acidic.

Dosage and Administration Information

Administration Protocol for Xitrin

Specific instructions for the use of the product branded as Xitrin are not currently established in standardized descriptive records.


Administration Scope

Guideline Status/Statement
Route of Administration Undocumented.
Dosing Schedule No standardized dosing rules (e.g., strength, interval) are identified.
Timing in relation to meals No specific instruction regarding administration with or without food is documented.
Age-Group Rules No age-specific use rules or adjustments are detailed.

Procedural Directives

Guideline Statement
Preparation Requirements No preparation steps (e.g., dilution, reconstitution) are stated.
Missed-Dose Instructions Guidance for managing a missed dose is not available.
Special Conditions No special procedural steps (e.g., patient positioning, monitoring requirements prior to administration) are explicitly documented.

Step Sequence

No specific procedural steps for the administration of Xitrin are available within the records reviewed. The full Summary of Product Characteristics (SmPC) detailing this information is required to establish the use protocol.

Recent Clinical Evidence

Research evidence / Overview of Studies for Xitrin

Evidence for Use in Preventing Recurrent Kidney Stones

Research examining the use of citrate salts, the active components in Xitrin, has mainly focused on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that combine the results of multiple trials. This body of research was studied for its potential role in addressing the risk of the formation of new stones (recurrence) in adults who have a history of stone disease. Studies explored how the treatment affects important chemical indicators in the urine, such as the level of urinary pH and the amount of urinary citrate. Citrate is a natural substance that was studied for its potential role in stone crystallization.

Studies report how measured biomarkers evolved in the observed populations. Research highlights changes measured during the study period, showing that the administration of citrate salts was associated with a consistent shift toward a less acidic urine environment. Findings describe patterns observed over clinical observation periods of up to five years, indicating that research examined and reported on differences in the rate of new stone formation compared to control groups in the populations studied.

Evidence for Use in Managing Chronic Metabolic Acidosis

The research base for using citrate salts to address the body’s acid-base imbalance stems from various studies, including those that compare it to other alkali therapies in patients with conditions like Renal Tubular Acidosis (RTA). Research examined whether the administration of citrate salts was associated with changes in key blood markers. The primary outcomes studied included changes in serum bicarbonate levels and shifts in serum potassium concentrations. These studies were conducted on adults and children diagnosed with RTA and chronic metabolic acidosis.

Studies monitored and reported measurements indicating that the use of citrate salts was consistently associated with a shift toward higher measured concentrations of serum bicarbonate. Non-inferiority trials were designed to evaluate the profile of measured outcomes for citrate salts relative to other alkali therapies used to manage acidosis. Long-term studies (up to two years) in the RTA population described sustained changes in blood acid levels observed over the observation period.

Research Gaps and Areas of Uncertainty

Research highlights what is known and what is still uncertain about the use of citrate salts. One key research limitation is the continued need for high-quality, long-term studies that directly compare the different available citrate salt formulations (potassium only vs. sodium/potassium combination) on clinical endpoints beyond biomarker changes. Data for certain groups are limited, and research provides context that these findings reflect group patterns, but does not determine whether an individual will respond similarly.

Key Studies & References

  1. Potassium Citrate: Treatment and Prevention of Recurrent Calcium Nephrolithiasis
  2. Renal Tubular Acidosis (Clinical approach, diagnosis, and management)

Frequently Asked Questions (FAQ)

Common questions about Xitrin (FAQ)


Q: How long does it take for Xitrin to start working?

Official information regarding the way Xitrin works suggests that the desired therapeutic effect, which is the increase in urinary citrate, can begin within the first hour after taking a single dose. This elevated level of urinary citrate can then last for approximately 12 hours. This process is designed to help modulate acid-base balance and urine pH.


Q: Does Xitrin cause drowsiness or fatigue?

Regulatory documents list side effects that can include fatigue or weakness, as well as dizziness. These effects are generally associated with more serious adverse reactions related to high potassium or high sodium levels in the body, which require clinical monitoring. These effects are not listed among the common adverse reactions documented for the drug.


Q: Are there any long-term side effects from taking Xitrin?

The official safety profile notes that some minor gastrointestinal issues, such as nausea, diarrhea, and abdominal discomfort, may persist with long-term use of the product. Additionally, a serious risk documented for oral potassium products, like Xitrin, is the potential for gastrointestinal lesions or ulceration.


Q: Can I take Xitrin if I'm already taking a multivitamin?

Official label warnings indicate that taking Xitrin, which is a source of potassium, alongside a multivitamin that also contains potassium, may increase the potential risk of developing hyperkalemia (high potassium levels). Furthermore, Xitrin's effect of making the urine less acidic might reduce the absorption of certain ingredients found in some multivitamins.


Q: Can teenagers or children take Xitrin?

The official product information states that the safety and effectiveness of Xitrin have not been established for the general pediatric population (children and teenagers). For children under two years of age, use is based solely on the consultation and discretion of a healthcare provider. Use in these groups is generally determined by a healthcare provider after careful consideration.


Q: What happens if I forget to take a dose of Xitrin?

Official patient information advises that if a dose is missed, it can be taken as soon as it is remembered. However, if it is already close to the time for your next scheduled dose, only that next dose is generally recommended. Patients are advised against taking double or extra doses to make up for a missed one.


Q: Can Xitrin affect my ability to drive or operate machinery?

The product information lists potential adverse effects, which, while uncommon, include dizziness and mental confusion. Patients are advised to be aware that if these effects occur, their ability to drive or safely operate machinery could potentially be impaired.


Q: What's the difference between Xitrin and an antibiotic?

The official classification of Xitrin is an Alkalinizing Agent, used primarily for managing the body's acid-base balance and making the urine less acidic. In contrast, an antibiotic is a different class of drug specifically used to treat infections caused by bacteria, meaning Xitrin is not used to fight infections.


Q: Can Xitrin be used during pregnancy or while breastfeeding?

Official regulatory documents state that use during pregnancy is generally not recommended unless the therapeutic benefit is judged to be clearly necessary. Similarly, for breastfeeding, it is unknown if the medication affects the potassium content of human milk, so use should only be considered when clearly needed.


Q: Do I need a prescription to get Xitrin?

Yes, Xitrin is clearly designated in its official product information as a Human Prescription Drug. It cannot be legally dispensed without a valid prescription from a licensed healthcare provider.


Q: Are there any known food interactions with Xitrin?

Regulatory guidance suggests that the product should be taken with meals, or within 30 minutes after meals or a bedtime snack. This administration timing is primarily intended to minimize the potential for gastrointestinal discomfort and upset.


Q: Why do some people say Xitrin didn't work for them?

Clinical pharmacology data indicates that the effectiveness of Xitrin can be variable depending on the individual's baseline chemical profile. For example, in patients who have very low urinary citrate levels, the drug may be relatively ineffective in achieving the desired increase in citrate, which may be a factor in an individual's perceived lack of response.


Q: Can I crush or split Xitrin tablets?

Xitrin is supplied as an oral solution (a liquid), not as a tablet. The instructions for use advise that the solution should be diluted in water before consumption. Therefore, it is not a solid dose form intended to be crushed, split, or chewed.


Q: Does Xitrin affect blood pressure?

Official warnings and precautions advise that use of Xitrin requires careful monitoring in patients with pre-existing conditions such as hypertension (high blood pressure) or cardiac failure. The presence of sodium in the formula is a factor that often requires caution in managing these patient populations.


Q: Can Xitrin be taken with birth control pills?

Official warnings state that certain hormonal contraceptives, specifically those containing the ingredient drospirenone, may increase the risk of hyperkalemia (high potassium levels) when used alongside Xitrin. In such cases, potassium level monitoring may be clinically necessary.


Q: Is Xitrin safe for older adults?

Regulatory information indicates that the risk of developing hyperkalemia (dangerously high potassium levels) is heightened in older adults due to the common age-related decline in kidney function. Therefore, use in this population requires careful monitoring, although no specific information is available regarding the relationship of age to the drug's overall therapeutic effects.


Q: Is there a generic version of Xitrin available?

Yes, the active ingredients in Xitrin—Potassium Citrate and Sodium Citrate—are available in generic formulations as well as under different brand names. These products contain the same chemical salts used to manage acid-base balance.


Q: Does Xitrin come in different strengths?

Yes, regulatory documents show that oral solutions containing the active components, Sodium Citrate and Citric Acid, are commonly available in different strengths (concentrations). This allows prescribers to adjust the exact amount of citrate and electrolytes a patient receives.


Q: What should I do if the side effects of Xitrin are bothering me?

Patient information suggests that minor gastrointestinal issues may often be eased by taking the dose with meals or a snack. If side effects persist or are significantly bothersome, clinical guidance may involve reducing the dose or, in the case of serious reactions, discontinuing the medication.


Q: Is Xitrin more effective if taken with food?

While taking Xitrin after meals or snacks is officially recommended, the reason is primarily to help prevent gastrointestinal discomfort and to enhance the palatability of the solution. The official information does not specifically state that taking it with food increases its therapeutic effectiveness.


Q: What kind of research has been done on Xitrin?

Official clinical studies have focused on evaluating the drug's effectiveness in managing two main conditions: hypocitraturic calcium oxalate nephrolithiasis, which involves the formation of certain kidney stones, and in managing chronic metabolic acidosis associated with Renal Tubular Acidosis (RTA).


Q: Are there any lifestyle changes recommended while taking Xitrin?

Official patient counseling information often advises that patients maintain a high fluid intake and may need to adhere to a special diet, such as a salt restriction.


Q: Is the effectiveness of Xitrin proven by clinical trials?

Yes, Xitrin is indicated and approved for specific conditions based on clinical trials that demonstrated its ability to achieve key therapeutic outcomes. These outcomes include raising urinary citrate levels and adjusting urine pH to a less acidic level.


Q: Why is Xitrin taken once a day by some people and twice by others?

The official product information indicates that the dosage frequency is tailored to the individual patient and the desired therapeutic effect. Regimens can vary, with some requiring the solution to be taken two to three times per day, or sometimes up to four times daily (after meals and at bedtime), depending on the severity of the condition being managed.

How should Xitrin be stored and disposed of?

How to Store and Dispose of Xitrin?

Official Storage Conditions

Xitrin oral solution must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from freezing and excessive heat to maintain its stability and integrity. The container must be kept tightly closed and should be dispensed in a light-resistant container.

Handling and Protection

It is mandatory to shake the solution well before using. To ensure safety, the medication must be kept out of the reach of children, as required by the labeling for prescription products. The container should have a child-resistant closure.

Disposal Instructions

Any unused or expired Xitrin must be disposed of according to applicable local laws and regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xitrin found in:

A-Z Index: